Welcome to our dedicated page for Mountain Vy Md news (Ticker: MVMDF), a resource for investors and traders seeking the latest updates and insights on Mountain Vy Md stock.
Mountain Valley MD Holdings Inc. reports developments across commercialization of its patented Quicksome™ and Quicksol™ formulation technologies, its licensed Agrarius™ agricultural plant signaling product, and related branded nutraceutical initiatives. News about MVMDF commonly covers nutraceutical product formats, agricultural product evaluations, regional distribution and regulatory work, and applications for husbandry animals and aquatic species.
Company updates also include capital actions such as private placements and shares-for-debt transactions, stock option grants, advisor and board appointments, and shareholder or governance matters tied to its public-company status.
Mountain Valley MD Holdings Inc. (CSE: MVMD) has announced promising results from its BSL-4 lab COVID-19 study involving its solubilized Ivermectin technology, Ivectosol™. The study demonstrated that a dose of 2.5 mg/kg effectively cleared the B.1.1.7 variant, with in vitro tests confirming antiviral activity against other variants. The company is now advancing to phase one human trials focusing on efficacy and safety of Ivectosol™ sublingual wafers. The breakthrough study marks a significant validation of Ivectosol™ in combating COVID-19 variants.
Mountain Valley MD Holdings Inc. (MVMDF) has announced the filing of a novel cancer adjuvant patent and the initiation of pre-clinical trials for Ivectosol™ targeting triple-negative breast cancer, metastatic melanoma, and lung carcinoma. The company aims to leverage the anti-cancer properties of ivermectin, demonstrated in previous studies, to enhance current chemotherapy and immunotherapy protocols. The first results from these trials are anticipated by the end of June 2021.
Mountain Valley MD Holdings Inc. (MVMD) is set to transition from the OTC Pink Sheets to the OTCQB Venture Marketplace on February 16, 2021, trading under the symbol MVMDF. This move is aimed at enhancing visibility and accessibility for U.S. investors, allowing for broader participation in the company's growth. The OTCQB Market is recognized for early-stage companies and offers improved trading experiences, aligning with MVMD's goal of increasing share liquidity. The company is focused on innovative drug delivery technologies in the health and wellness sectors.